Q1 2025 Dexcom Inc Earnings Call Transcript
Key Points
- DexCom Inc (DXCM) reported a 14% organic revenue growth in Q1 2025 compared to Q1 2024, marking the second consecutive quarter of reaccelerating revenue growth.
- The company successfully navigated short-term supply dynamics while maintaining strong demand in the US market, ensuring limited customer disruption.
- DexCom Inc (DXCM) expanded its commercial reach, leading to record levels of new customer starts, particularly from the type 2 non-insulin population.
- The introduction of Stelo, the first over-the-counter CGM, and broader coverage within the type 2 market have been well-received, enhancing customer experience.
- DexCom Inc (DXCM) announced a $750 million share repurchase program, reflecting confidence in its strong revenue and cash flow growth outlook.
- DexCom Inc (DXCM) received a warning letter from the FDA related to observations at its San Diego and Mesa facilities, requiring corrective actions.
- The company's gross profit margin decreased to 57.5% in Q1 2025 from 61.8% in Q1 2024, impacted by supply chain issues and increased freight costs.
- Despite strong Q1 performance, DexCom Inc (DXCM) maintained its full-year revenue guidance, indicating caution about future quarters.
- The international revenue growth was below expectations, with some choppiness due to the timing of coverage wins and supply dynamics.
- DexCom Inc (DXCM) faces ongoing inflationary pressures and potential tariff impacts, which could affect global manufacturing costs.
Welcome to the DexCom first-quarter 2025 earnings release conference call. My name is Louella, and I will be your operator for today's call. (Operator Instructions) As a reminder, the conference is being recorded.
I will now turn the call over to Sean Christensen, Vice President of Finance and Investor Relations. Sean, you may begin.
Welcome to DexCom's first-quarter 2025 earnings call. Our agenda begins with Kevin Sayer, DexCom's Chairman, President and CEO, who will summarize our recent highlights and ongoing strategic initiatives; followed by a financial review and outlook from Jereme Sylvain, our Chief Financial Officer.
Following our prepared remarks, we will open the call up for your questions. At this time, we ask analysts to limit themselves to one question each so we can provide an opportunity for everyone participating today. Please note that there are also slides available related to our first-quarter 2025 performance on the DexCom Investor Relations
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
